CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
18 hedge funds and large institutions have $957K invested in CERo Therapeutics in 2024 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, reducing their positions, and 7 closing their positions.
199% more capital invested
Capital invested by funds: $320K → $957K (+$637K)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
29% more funds holding
Funds holding: 14 → 18 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$927K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$143K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$38.9K |
| 4 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
+$27.3K |
| 5 |
Goldman Sachs
New York
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$14.7K |
| 2 |
HF
HRT Financial
New York
|
-$7K |
| 3 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$6.89K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$5.27K |
| 5 |
SG
StoneX Group
New York
|
-$1.55K |
CERO Hedge Fund Activity: Q4 2024 in Review
18 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2024, worth a combined $957K — up 199% from $320K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CERO positions and 7 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Arch Venture Management, adding an estimated $927K. The largest seller was Geode Capital Management, exiting entirely with an estimated $14.7K sold.
- 18 institutional investors held CERo Therapeutics (CERO) as of Q4 2024, up from 14 in Q3 2024.
- Funds reported $957K of CERo Therapeutics stock for Q4 2024, up 199% quarter-over-quarter.
- 11 funds opened new CERo Therapeutics positions in Q4 2024 and 7 closed out, a net change of +4 holders.
- The largest CERo Therapeutics buyer in Q4 2024 was Arch Venture Management, an estimated $927K added.
- The largest CERo Therapeutics seller in Q4 2024 was Geode Capital Management, an estimated $14.7K sold.
Based on aggregated 13F filings for Q4 2024.